Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Scraps Insulin Peglispro Amid Too Much Uncertainty

This article was originally published in Scrip

Executive Summary

Investors greeted Eli Lilly & Co.'s news with open arms the company was dumping its late-stage investigational types 1 and 2 diabetes treatment basal insulin peglispro (BIL) after deciding there was too much uncertainty about the product's future after issues arose concerning changes in liver fat in its Phase III IMAGINE trials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel